Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 275

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study

Open access
Biran, Noa, Ip, Andrew, Ahn, Jaeil, Go, Ronaldo C, Wang, Shuqi, Mathura, Shivam, Sinclaire, Brittany A, Bednarz, Urszula, Marafelias, Michael, Hansen, Eric, Siegel, David S, Goy, Andre H, Pecora, Andrew L, Sawczuk, Ihor S, Koniaris, Lauren S, Simwenyi, Micky, Varga, Daniel W, Tank, Lisa K, Stein, Aaron A, Allusson, Valerie, Lin, George S, Oser, William F, Tuma, Roman A, Reichman, Joseph, Brusco, Louis, Carpenter, Kim L, Costanzo, Eric J, Vivona, Vincent, Goldberg, Stuart L·2020·The Lancet Rheumatology

Abstract

Background Tocilizumab, a monoclonal antibody directed against the interleukin-6 receptor, has been proposed to mitigate the cytokine storm syndrome associated with severe COVID-19. We aimed to investigate the association between tocilizumab exposure and hospital-related mortality among patients requiring intensive care unit (ICU) support for COVID-19. Methods We did a retrospective observational cohort study at 13 hospitals within the Hackensack Meridian Health network (NJ, USA). We included patients (aged ≥18 years) with laboratory-confirmed COVID-19 who needed support in the ICU. We obtained data from a prospective observational database and compared outcomes in patients who received tocilizumab with those who did not. We applied a multivariable Cox model with propensity score matching to reduce confounding effects. The primary endpoint was hospital-related mortality. The prospective observational database is registered on ClinicalTrials.gov, NCT04347993. Findings Between March 1 and April 22, 2020, 764 patients with COVID-19 required support in the ICU, of whom 210 (27%) received tocilizumab. Factors associated with receiving tocilizumab were patients' age, gender, renal function, and treatment location. 630 patients were included in the propensity score-matched population, of whom 210 received tocilizumab and 420 did not receive tocilizumab. 358 (57%) of 630 patients died, 102 (49%) who received tocilizumab and 256 (61%) who did not receive tocilizumab. Overall median survival from time of admission was not reached (95% CI 23 days–not reached) among patients receiving tocilizumab and was 19 days (16–26) for those who did not receive tocilizumab (hazard ratio [HR] 0·71, 95% CI 0·56–0·89; p=0·0027). In the primary multivariable Cox regression analysis with propensity matching, an association was noted between receiving tocilizumab and decreased hospital-related mortality (HR 0·64, 95% CI 0·47–0·87; p=0·0040). Similar associations with tocilizumab were noted among subgroups requiring mechanical ventilatory support and with baseline C-reactive protein of 15 mg/dL or higher. Interpretation In this observational study, patients with COVID-19 requiring ICU support who received tocilizumab had reduced mortality. Results of ongoing randomised controlled trials are awaited. Funding None.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2665-9913(20)30277-0

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 275

Metadata

Authors
Biran, N., Ip, A., Ahn, J., Go, R. C., Wang, S., Mathura, S., Sinclaire, B. A., Bednarz, U., Marafelias, M., Hansen, E., Siegel, D. S., Goy, A. H., Pecora, A. L., Sawczuk, I. S., Koniaris, L. S., Simwenyi, M., Varga, D. W., Tank, L. K., Stein, A. A., Allusson, V., Lin, G. S., Oser, W. F., Tuma, R. A., Reichman, J., Brusco, L., Carpenter, K. L., Costanzo, E. J., Vivona, V., & Goldberg, S. L.
Venue
The Lancet Rheumatology
Publisher
Elsevier BV
Published
2020-10
Volume
2
Issue
10
Pages
e603-e612
ISSN
2665-9913 (ISSN-L)
OpenAlex
W3048601848
Cited by
275
References
26
FWCI
7.91
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. https://app.cochat.ai/papers/10.1016/s2665-9913(20)30277-0
The paper
Biran, N., Ip, A., Ahn, J., Go, R. C., Wang, S., Mathura, S., Sinclaire, B. A., Bednarz, U., Marafelias, M., Hansen, E., Siegel, D. S., Goy, A. H., Pecora, A. L., Sawczuk, I. S., Koniaris, L. S., Simwenyi, M., Varga, D. W., Tank, L. K., Stein, A. A., . . . Goldberg, S. L. (2020). Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. The Lancet Rheumatology. https://doi.org/10.1016/s2665-9913(20)30277-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.